Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member
tabling member	label

Search

1685620

registered interest
date	29/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of introducing financial incentives for businesses to manufacture medicines in the UK.
tabling member constituency	Stoke-on-Trent North
tabling member printed	Jonathan Gullis
uin	11887
answer	answer is ministerial correction date of answer 05/02/2024 answer text <p>In 2021, the Government’s Life Sciences Vision set out our ambition to create a globally competitive environment for Life Sciences manufacturing investments. To help meet these ambitions, the Government has launched three capital grant schemes, with up to £118 million of grant funding allocated. To date, these schemes have delivered £416 million of public and private investment and helped create or secure over 1,400 jobs. We anticipate announcing the next round of grant recipients over spring 2024.</p><p>In 2023, the Government announced a further £520 million of funding for Life Sciences manufacturing. This funding, available from 2025 over five years, will help to ensure that the United Kingdom remains a world leading location for Life Sciences manufacturing investments.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 05/02/2024 13:20:33 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4814 label Biography information for Jonathan Gullis

1675319

registered interest
date	29/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent progress she has made on negotiations with the pharmaceutical sector.
tabling member constituency	Ashfield
tabling member printed	Lee Anderson
uin	900487
answer	answer is ministerial correction date of answer 05/12/2023 answer text <ul><li><p>A new voluntary scheme has been agreed in principle by the government, NHS England and the Association of the British Pharmaceutical Industry and will run for 5 years from 1st January 2024.</p></li><li><p>It is a landmark deal that is set to save the NHS around £14 billion over 5 years in medicines costs that can be used to provide the best possible treatment and care for NHS patients, grow the workforce and cut waiting lists.</p></li></ul> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 05/12/2023 18:00:39 answering member 4044 label Biography information for Andrew Stephenson previous answer version 5574 answering member constituency South Northamptonshire answering member printed Andrea Leadsom answering member 4117
tabling member	4743 label Biography information for Lee Anderson

1657762

registered interest
date	04/09/2023
answering body	Department for Business and Trade
answering dept id	214
answering dept short name	Business and Trade
answering dept sort name	Business and Trade
hansard heading	Drugs: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business and Trade, whether her Department has made an assessment of the resilience of the pharmaceutical-grade fill/finish sector.
tabling member constituency	Newcastle upon Tyne Central
tabling member printed	Chi Onwurah
uin	197403
answer	answer is ministerial correction date of answer 07/09/2023 answer text <p>The Department’s life sciences team is responsible for is attracting investment and enabling exports. The last assessment of UK fill/finish capacity was carried out in mid-2021 by the Vaccines Taskforce. The Department for Business and Trade in collaboration with the Department for Science, Innovation and Technology, is currently undertaking a voluntary manufacturing survey of the pharmaceutical industry in the UK.</p><p> </p><p>The Department is also working closely with the DSIT/DHSC on the Biomanufacturing Fund, which will provide up to £38m in capital grants to incentivise investment in the manufacture of vaccines and biotherapeutics, which could include fill/finish providers.</p> answering member constituency Wealden answering member printed Ms Nusrat Ghani question first answered 07/09/2023 17:16:45 answering member 4460 label Biography information for Ms Nusrat Ghani
tabling member	4124 label Biography information for Chi Onwurah

1653503

registered interest
date	17/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many prosecutions of pharmaceutical companies withholding information from the Medicines & Healthcare Products Regulatory Agency have occurred in the last twenty years.
tabling member constituency	Lancaster and Fleetwood
tabling member printed	Cat Smith
uin	194463
answer	answer is ministerial correction date of answer 19/07/2023 answer text <p>While the Medicines and Healthcare products Regulatory Agency’s (MHRA) records dating back to 2003 are incomplete, it is unable to identify any prosecutions that have occurred as a result of a pharmaceutical company withholding information.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/07/2023 10:05:48 answering member 4423 label Biography information for Will Quince
tabling member	4436 label Biography information for Cat Smith

1603969

registered interest
date	14/03/2023
answering body	Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Drugs: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Chancellor of the Exchequer, what fiscal steps he is taking to encourage pharmaceutical companies to invest in the UK economy.
tabling member constituency	Warrington North
tabling member printed	Charlotte Nichols
uin	165421
answer	answer is ministerial correction date of answer 22/03/2023 answer text <p>At Spring Budget, the Chancellor set out how the government will re-invigorate a culture of enterprise with support for business investment and innovation, including in the pharmaceutical industry. Companies across the life sciences sector will benefit from fiscal policies included in the Budget, such as full expensing of capital expenditure, research and development (R&amp;D) tax relief reform and tax simplification. Government is also focusing on smarter regulation to support innovation, and with £10m extra funding over the next 2 years, the MHRA will maximise its use of Brexit freedoms and accelerate patient access to treatments developed by the sector.</p> answering member constituency South Suffolk answering member printed James Cartlidge question first answered 22/03/2023 12:05:44 answering member 4519 label Biography information for James Cartlidge
tabling member	4799 label Biography information for Charlotte Nichols

1600761

registered interest
date	02/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the implications for his policies of proposals published on 1 March 2023 by the Association of the British Pharmaceutical Industry for an Investment Facility, including the potential impact of those proposals on (a) clinical research capacity, (b) genomics capacity, (c) real world data capability and (d) equitable medicines use.
tabling member constituency	Coventry North West
tabling member printed	Taiwo Owatemi
uin	157050
answer	answer is ministerial correction date of answer 13/03/2023 answer text <p>The Department has seen the proposals published on 1 March; they will be considered as part of formal negotiations for a future voluntary scheme.</p><p>The Government is open to ideas about how a successor to the voluntary scheme for branded medicines pricing and access should operate from 2024 onwards and will work with industry to agree a mutually beneficial successor that supports better patient outcomes, ensures the sustainability of National Health Service spend on branded medicines, and enables a strong life sciences industry.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/03/2023 15:34:15 answering member 4423 label Biography information for Will Quince
tabling member	4779 label Biography information for Taiwo Owatemi

1582716

registered interest
date	01/02/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of (a) the competitiveness of the UK pharmaceutical industry for (i) conducting clinical trials and (ii) research and development and (b) the impact of the level of use of innovative medicines in the NHS on outcomes for patients.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	137769
answer	answer is ministerial correction date of answer 09/02/2023 answer text <p>The life sciences sector is among the most valuable and strategically important in the United Kingdom’s economy. The latest edition of the Government’s Life Sciences Competitiveness Indicators shows that in 2020, the UK ranked sixth out of 10 comparator countries for our share of patients recruited to a subset of commercial global studies for novel medicines. The UK also ranked seventh for the time taken between clinical trial application and first dose to first patient. This is up from tenth in 2019.</p><p>The indicators also show that, in 2020, the UK pharmaceutical industry spent over £5 billion on research and development (R&amp;D) and has consistently been the largest industry to spend on R&amp;D in the UK, making up more than a fifth of all R&amp;D performed by industry between 2014 and 2020.</p><p>The National Health Service in England is internationally competitive in adopting innovative medicines. Industry data shows that there are five treatments available in England for every four in Europe and almost a third more cancer drugs.</p> answering member constituency Colchester answering member printed Will Quince question first answered 09/02/2023 13:56:52 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon

1582447

registered interest
date	31/01/2023
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Drugs: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what support he is providing to businesses in the pharmaceutical sector to (a) expand their premises and (b) manufacture more products.
tabling member constituency	Witham
tabling member printed	Priti Patel
uin	136593
answer	answer is ministerial correction date of answer 07/02/2023 answer text <p>In 2021, the Government published the Life Sciences Vision, which set out an ambition to create a globally competitive environment for Life Science manufacturing investments. To help meet these ambitions and incentivise globally mobile manufacturing investments in the UK, the Office for Life Sciences launched the £60 million Life Sciences Innovative Manufacturing Fund (LSIMF) in March 2022. The LSIMF will provide capital grants for investment in the manufacture of human medicines (drug substance and drug product), medical diagnostics and medical technology products. The fund has received a large number of high-quality applications and we expect to announce the successful grant awards from spring 2023.</p> answering member constituency Wealden answering member printed Ms Nusrat Ghani question first answered 07/02/2023 15:38:59 answering member 4460 label Biography information for Ms Nusrat Ghani
tabling member	4066 label Biography information for Priti Patel

1580945

registered interest
date	25/01/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Manufacturing Industries
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the report by the Medicines Manufacturing Industry Partnership Fulfilling the potential identified in the Government's Life Sciences Vision, published on 24 January, what assessment they have made of its findings that the UK has seen (1) a significant loss of traditional medicines manufacturing capacity over the last 25 years, (2) 7,000 jobs lost, and (3) a fall in production volumes of 29 per cent since 2009.
tabling member printed	Lord Hunt of Kings Heath
uin	HL5074
answer	answer is ministerial correction date of answer 06/02/2023 answer text <p>Life Sciences pharmaceutical manufacturing was responsible for approximately £20.1 billion worth of exports in 2021. This figure is based on a US dollar figure of $27.7 billion, using the 2021 OECD average conversion rate.</p><p>The official statistics from the Office for Life Sciences show that employment in core biopharmaceutical manufacturing employment declined between 2009 and 2019 but increased by 5% between 2019 and 2021. The Life Sciences Vision sets out an ambition to create a globally competitive environment for Life Science manufacturing investments. To help meet these ambitions, the Government launched the £60 million Life Sciences Innovative Manufacturing Fund in March 2022 to incentivise globally mobile manufacturing investments in the United Kingdom.</p> answering member printed Lord Markham question first answered 06/02/2023 18:01:55 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1329772

registered interest
date	04/06/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential effect of representation of pharmaceutical corporations on the General Pharmaceutical Council on regulatory oversight in the pharmaceutical industry.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	10533
answer	answer is ministerial correction date of answer 09/06/2021 answer text <p>No such assessment has been made.</p><p>The General Pharmaceutical Council regulates pharmacists, pharmacy technicians and pharmacies in Great Britain and has no role in regulating the pharmaceutical industry.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 10534 question first answered 09/06/2021 16:00:23 answering member 4380 label Biography information for Jo Churchill
tabling member	4510 label Biography information for Helen Hayes